[DISCLOSURE]
Samsung BioLogics (207940) announced on Sept. 12 that it has signed a CMO contract worth 34.56 billion won (US$30.68 million) with Immunomedics.
This amounts to 7.4 percent of its 2017 revenue and the contract is valid until Dec. 31, 2025.
By Hwang You-mee (
glamazon@heraldcorp.com)